Complement activation products in acute heart failure: Potential role in pathophysiology, responses to treatment and impacts on long-term survival by Trendelenburg, Marten et al.
 Complement activation products in acute heart failure: 
potential role in pathophysiology, response to treatment 
and impact on long-term survival 
 
Marten Trendelenburg, MD1,2*; Fabio Stallone, MD1,3,4*; Kateryna Pershyna, MD3,4; 
Timo Eisenhut, MD3,4,; Raphael Twerenbold, MD3,4,; Karin Wildi, MD3,4,5; Denise 
Dubler, PhD2; Lucia Schirmbeck, MSc2; Christian Puelacher, MD3,4; Maria Rubini 
Gimenez, MD3,4; Zaid Sabti, MD3,4; Luca Osswald, MD3,4; Tobias Breidthardt, MD1,3,4; 
and Christian Mueller, MD3,4 
1Division of Internal Medicine, University Hospital Basel, Switzerland; 2 Laboratory for Clinical 
Immunology, Department of Biomedicine, University Hospital Basel, Switzerland; 
3Department of Cardiology; 4Cardiovascular Research Institute Basel (CRIB) , University 
Hospital Basel, Switzerland; 5 Department of Intensive Care Medicine, University Hospital 
Basel, Switzerland 
*both authors have contributed equally and should be considered as first author 
 
 
 
Word Count:  6000 
Key Words: acute heart failure, complement factors, complement activation products 
Correspondence to: Prof. Dr. Christian Müller, Department of Cardiology, University 
Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland 
E-mail: christian.mueller@usb.ch 
2 
 
 
Abstract 
Background: Previous studies indicated a correlation between heart failure, 
inflammation and poorer outcome. However, the pathogenesis and role of 
inflammation in acute heart failure (AHF) is incompletely studied and understood.  The 
aim of our study was to explore the potential role of innate immunity -quantified by 
complement activation products (CAP)- in pathophysiology, response to treatment and 
impact on long-term survival in AHF. 
Methods: In a prospective study enrolling 179 unselected patients with AHF, plasma 
concentrations of C4d, C3a, and sC5b-9 were measured in a blinded fashion on the 
first day of hospitalization and prior to discharge. The final diagnosis including the AHF 
phenotype was adjudicated by two independent cardiologists. Long-term follow-up was 
obtained. Findings in AHF were compared to that obtained in 75 healthy blood donors 
(control group)  
Results: Overall, concentrations of all three CAP were significantly higher in patients 
with AHF than in healthy controls (all p<0.001). In an age-adjusted subgroup analysis, 
significant differences could be confirmed for concentrations of C4d and sC5b-9, and 
these parameters further increased after 6 days of in-hospital treatment (p<0.001). In 
contrast, C3a levels in AHF patients did not differ from those of the control group in the 
age-adjusted subgroup analysis, and remained constant during hospitalisation. 
Concentrations of C4d, C3a and sC5b-9 were significantly higher when AHF was 
triggered by an infection as compared to other triggers (p<0.001). In addition, CAP 
levels significantly correlated with each other (r=0.55 to 0.76), but did not predict death 
within 2 years.  
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Conclusions:  Activation of complement with increased plasma levels of C4d and 
sC5b-9 at admission and increasing levels during AHF treatment seems to be 
associated with AHF, in particular when AHF was triggered by infection. However, 
complement activation products do not have a prognostic value in AHF 
 
 
Introduction  
Acute heart failure (AHF) is the most common cause of hospital admission in patients 
older than 65 years of age and continues to have unacceptably high rates of mortality 
and morbidity. 1-6 Poor outcome in AHF may at least in part be due to incomplete 
understanding of the pathophysiology of AHF. In addition, incomplete understanding 
of AHF pathophysiology may have contributed to the fact that none of the currently 
available treatments is supported by an appropriately powered positive randomized 
controlled study and none of the recently completed phase III studies of novel drugs 
demonstrated clear clinically relevant benefit. 1, 2, 7-9 
More in-depth knowledge of pathogenic mechanisms being involved in AHF 
seem to be a prerequisite for more targeted and successful interventions. E.g. in acute 
myocardial infarction identification of thrombotic plaque rupture as its key 
pathophysiological hallmark has led to the enormous treatment successes in patients 
suffering from AMI by antiplatelet therapy, anticoagulation, statins, and early 
revascularization.10 
The complement system is one of the key components of innate immunity. After 
activation it has at least three physiological functions: Defense against infections, 
bridging innate and adaptive immunity, and clearing apoptotic cells and immune 
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complexes. The complement system achieves that by the opsonisation of pathogens 
for phagocytes, the release of inflammatory mediators and the induction of cell lysis 
through the formation of the membrane attack complex. 11-21 On the other hand, 
inappropriate complement activation is pathogenic and may be involved in various 
autoimmune diseases. The complement system features more than 20 different serum 
proteins that are produced by a variety of cells. The interaction of these proteins 
constitutes a meticulously regulated cascade of activation steps (Figure 1). Finally, all 
activation steps converge on the complement component C3. In the heart, activated 
C3 (C3a) caused tachycardia, impairment of atrioventricular conduction, and left 
ventricular contractility. 11-21 
Pilot studies have suggested an activation of inflammatory pathways in chronic 
HF and regression after treatment as well as an association between inflammation and 
poorer outcome.22-26 However, the pathogenic mechanisms leading to the activation of 
the immune system and to a poorer outcome are largely unknown. While several recent 
studies have examined complement components in patients with AMI, their possible 
role in heart failure in general and AHF in particular are still unclear.11-21  
Considering the association between inflammation and CHF, poorer outcome 
and the incomplete understanding of the pathogenic mechanisms of inflammation in 
CHF we aimed to explore the activation of the innate immunity in AHF determining 
levels of complement activation products (CAP) C4d, C3a, and sC5b-9 in post hoc 
analysis of a population of AHF patients that were recruited in the context of a 
prospective study. We postulated that a higher degree of complement activation will 
be associated with poorer outcome in these patients. In addition, for a better 
understanding of the pathogenesis of complement-associated inflammation in AHF, 
we evaluated predictors of low and high CAP levels in this AHF population. 
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Methods 
Study design and population 
Unselected AHF patients presenting to the ED of the University Hospital Basel 
(Switzerland) were enrolled in this prospective observational study. More than 18 year-
old men and women, presenting with acute dyspnea as the main symptom and 
diagnosed as having AHF were recruited. All patients underwent a clinical assessment 
that included medical history, physical examination, 12-lead ECG, continuous ECG 
rhythm monitoring, pulse oximetry, standard blood test, and chest radiography. 
Treatment of patients was left to discretion of the attending physician. The final 
diagnosis, phenotype of heart failure and trigger of the acute decompensation was 
then adjudicated using all medical records pertaining to the patients (including results 
of standard investigations, response to therapy and B-type natriuretic peptide (BNP) 
values) by two independent cardiologists according to the current guidelines.1  
The study was conducted according to the principles of the Declaration of Helsinki and 
approved by the local ethics committee. Written informed consent was obtained from 
all participating patients. While recruitment was independent of renal function, patients 
with terminal kidney failure requiring chronic hemodialysis were excluded. For this 
analysis, patients with AHF triggered by ST-elevation MI and patients with cardiogenic 
shock were also excluded.  
Follow-up 
The primary prognostic endpoint was all cause-mortality during follow-up. After 3, 12 
and 24 months, patients were contacted by phone or by letter and were interviewed by 
trained researchers blinded to the results of laboratory testing. Information about all 
cardiovascular events since presentation at the emergency departement until death 
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was obtained by the patient’s family physician, the hospital’s diagnosis registry or the 
national registry on mortality. 
Control group 
In order to validate the measurements of the levels of complement activation products 
(CAP), we also determined CAP levels in 75 healthy blood donors. This age and 
gender unadjusted population then was used as a control group to compare levels of 
CAP in AHF with those in healthy subjects. 
 
Biochemical Analysis 
For all the patients, venous blood samples were collected in tubes containing 
potassium EDTA.  BNP was measured immediately using the Abbott Architect assay; 
otherwise, samples were centrifuged and frozen at -80°C until later analysis in a 
dedicated core laboratory. Plasma levels of three complement activation products 
(C4d, C3a, sC5b-9) were measured by enzyme-linked immunosorbent assays from 
samples taken on day 1 of hospitalization as well as one the day prior to discharge and 
using commercially available kits following the manufacturer’s instructions (C3a Plus 
MicroVue, C4d MicroVue, SC5b-9 Plus MicroVue, all Quidel, San Diego). In short, the 
C4d assay measures all C4d-containing fragments of C4 present in human plasma. In 
contrast, the C3a and sC5b-9 assays were designed to specifically detect complement 
activation products (CAP) with the C3a assay detecting a neo-epitope on C3a (C3a-
desArg) that is generated during complement activation, and the sC5b-9 immunoassay 
measuring the concentration of soluble terminal complement complexes. 
 
Statistical Analysis 
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Categorical variables are expressed as numbers and percentages, and continuous 
variables are expressed as medians and interquartile range.  
To evaluate a possible activation of the complement cascade in AHF, we compared 
levels of CAP in AHF patients with a control group of 75 healthy blood donors. Median 
values of CAP levels for AHF patients and the control group were compared by Mann-
Whitney U tests, and chi-squared tests was used to compare the gender distribution. 
Due to differences in age between patients and healthy controls, we performed an age-
related subgroup analysis only for those individuals with age of 60 to 69 years and 70 
to 79 years. Numbers of patients for other groups of age were considered to be too low 
for an explanatory power. To screen predictors for patients with levels of all three 
complement activation products being in the higher or lower tertile respectively, we 
primarily performed univariate logistic regression. We assumed that the class of 
patients with levels of complement activation products only in the highest or lowest 
tertile had the highest or lowest activation of the complement cascade. To the 
multivariate model we included age, sex, BMI and all variables associated with p-
values lower than 0.1 in the univariate analysis for lower or higher tertile. Correlation 
analyses were performed using Spearman rank correlation test. Receiver operating 
characteristic (ROC) and Kaplan Meier curves were constructed to assess prognostic 
value of complement activation products at admission with regard to 730-day mortality. 
Time to death during follow-up was compared between tertiles of complement 
activation products on admission and analysed by a log-rank test. COX-Regression 
analysis were ruled to asses a multivariable adjusted prognostic value regarding 
complement activation products at discharge with regard to 730-day mortality. 
Variables with p-value <0.1 and sex were included in the multivariate analysis. The 
multivariate model was the reference model to test the prognostic value of each 
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complement activation product at discharge as continous variable. All hypothesis 
testing was two-tailed and a P-value of 0.05 or below was considered statistically 
significant. All statistical analyses were performed using SPSS for Windows 22.0 (IBM) 
and MedCalc 11.2.1.0 (MedCalc Software). 
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Results 
 
Characteristics of Patients 
The baseline characteristics of the 179 AHF patients are shown in Table 1.  
 
 
Complement activation products (CAP) in AHF versus controls and 
response to treatment 
Concentrations of CAP were significantly higher (all p<0.001; Table 2) in patients with 
AHF as compared to a gender and age unadjusted control group (median age 56 years 
(IQR 47-68 years), 23% women (p<0.001 for comparisons with the AHF group)). A 
subgroup analysis for patients with age between 60 and 69 years as well as between 
70 and 79 years could confirm differences for levels of C4d and sC5b-9 (all p<0.001 
and p=0.002 for sC5b-9 in individuals with age of 70-79 years), whereas no difference 
in levels of C3a in AHF compared to the control group could be found (p= 0.432 and 
p=0.061, respectively).   Interestingly, while concentrations of C4d and sC5b-9 further 
increased during hospitalisation (p<0.001), concentrations of C3a remained constant 
(p=ns; Figure 2 (a) to (c)). 
Concentrations of CAP significantly correlated with each other (r=0.55 to 0.76). 
Spreading plots with best-fitted lines between the 3 different CAP are shown in Figure 
3 (a) to (c). The correlations were moderate to high: r= 0.64, p<0.001 for correlation 
between C3a and C4d; r= 0.76, p<0.001 for C3a and sC5b-9; r= 0.64, p<0.001 for C4d 
and sC5b-9). C4d, C3a and sC5b-9 had a weak correlation with CRP (r= 0.20, p=0.007, 
r= 0.004, p=0.963; r= 0.155, p= 0.40) and a low inverse correlation with BNP (r= -0.20, 
p= 0.007; r= -0.18, p= 0.015 and r = -0.30, p<0.001). Levels of C4d and C3a at 
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discharge showed no correlation with BNP at discharge (p=ns), but levels of sC5b-9 
had a small negative correlation with BNP at discharge (r=-0.154, p= 0.040). No 
correlation between CRP and complement activation products was found at discharge 
(p=ns) 
 
Complement activation products in patients with AHF and infectious trigger 
Concentrations of C4d, C3a and sC5b-9 were significantly higher when AHF was 
triggered by an infection as compared to other triggers (p<0.001, Table 3). Of note, 
levels of C4d and sC5b-9 were still significantly higher in patients without an infectious 
trigger than in the control group (p<0.001) while there was no difference for levels of 
C3a between patients with AHF but without infectious trigger and controls (p=0.160).
   
 
Complement activation products in patients with AHF and coronary artery 
disease with or without ischemic trigger 
Plasma concentrations for the three CAP were similar in patients with or without 
coronary artery diesease (CAD) (Online only Table 1). Patients with an ischemic trigger 
of AHF had slightly, but statistically not significant, higher concentrations of C4d and 
C3a when compared to patients without an ischemic cause.  (Online Only Table 2). 
Even after exclusion of patients with an infectious trigger there was no statistically 
significant difference (data not shown). 
 
Predictors of elevated or low complement activation products at AHF 
presentation 
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Univariate logistic regressions for the association of patients with all CAP in the lower 
and higher tertile are shown in the online only table 3.  After multivariate adjustement 
(Table 4), it could be observed that patients with complement activation products in the 
lower tertile had less often AHF associated with infection. Other variables did not reach 
statistical significance. Patients in the higher tertile were associated more often with 
lower BNP (OR 0.92 (0.85-1.00), p-value 0.050) and lower ALAT levels (OR 0.94 (0.90-
0.99), p-value 0.011).  
 
Complement activation products and long-term mortality in AHF 
There were 66 events in a 2-year follow up. 730-day follow ups were completed in 
43/113 (38%) patients without event and 1-year follow-up was completed in 112/113 
(99%).  
Concentrations at admission of all three investigated complement activation products 
did not predict death within 2 years.  Prognostic accuracy as quantified by the AUC is 
shown in Figure 4, Kaplan Meier survival curves in AHF patients classified according 
to tertile of each CAP are shown in Figure 5 (a) to (c). Mortality rate among different 
tertiles of CAPs was the same (Log rank =ns).  
In a multivariate analysis liver disease, eGFR and CRP at discharge were associated 
with mortality. Levels of complement activation products at hospital discharge were not 
associated with long-term mortality (table 5). 
 
Discussion 
This prospective study explored the possible pathogenic, diagnostic and prognostic 
role of complement factors in AHF by measuring plasma C4d, C3a, and sC5b-9 levels. 
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We report 4 major findings. First, when compared to an unadjusted control group of 
healthy blood donors, plasma concentrations of all three complement activation 
products (CAP) were significantly higher in patients with AHF. However, in a sub-group 
analysis for patients with 60 to 69 years and 70 to 79 years of age, differences could 
only be confirmed for levels of C4d and sC5b-9. Second, higher concentrations of C4d, 
C3a and sC5b-9 at admission were more often associated with an infection as trigger 
of AHF, as well as with lower BNP and ALAT levels. Patients with an ischemic trigger 
had slightly, but statistically not significant, higher concentrations of C4d and C3a at 
admission. Third, levels of C4d and sC5b-9 continued to rise during the hospitalisation, 
whereas levels of C3a remained stable, suggesting ongoing activation of the 
complement cascade in AHF via the classical and/or lectin pathways that is not rapidly 
influenced by the treatment of acute heart failure. Fourth, complement activation 
products at admission and discharge were not associated with long-term mortality in 
AHF.  
Our findings corroborate and extend findings from basic as well as pre-clinical 
and clinical models 11-21 suggesting that complement activation is mechanistically 
involved in adverse cardiac healing and remodeling after AMI. Complement inhibition 
consistently attenuated leukocyte recruitment following AMI highlighting the critical role 
of the complement cascade in triggering inflammation in the ischemic myocardium.  
However, the possible role of complement factors in AHF or chronic HF is still 
emerging. Recently, Gombos et al. examined stable outpatients with chronic HF and 
found an association between activated complement C3a and mortality or 
rehospitalisation due to progression of heart failure.16 Aukrust et al. found complement 
activation with chronic heart failure, while treatment with intravenous immunoglobulin 
seemed to reduce complement activation and increased left ventricular function during 
a 5-month follow-up period.14 In a recent study, Silva et al. reported on lower levels of 
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C3c and C4c being more often associated with high levels of BNP at admission for 
AHF, suggesting an activation of the complement cascade in AHF. In a multivariate 
analysis, low C3c levels at discharge were independently associated with the 6-month 
mortality.27 However, while we observed some association between complement 
activation products and BNP levels in our study as well, we could not find any 
association between complement activation products and mortality.  These differences 
might be due to the different parameters being measured (C3c and C4c versus C4d 
and C3a), different methods used for their quantification (nephelometry versus enzyme 
immunoassays) as well as differences in time and character of storage of samples prior 
to analysis.  
While this is one of the first studies to explore complement activation products in AHF, 
it is important to acknowledge several limitations. First, our study is moderate in size 
and recruited patients from a single institution, rendering it susceptible to inclusion 
bias. In this context, it is reassuring to note that baseline characteristics of this study 
were similar to e.g. large international AHF registries.28-30 Second, we measured only 
three activation products of the complement cascade allowing only limited conclusions 
on more subtle alterations in the complement system. Third, we cannot exclude effects 
due to the period of freezing at -80°C on complement split product levels that could 
only be minimized by e.g. determination of markers of complement activation in 
samples cooled immediately after blood collection. However, significant differences 
between samples of AHF patients having undergone the same handling procedures 
but having had different triggers of disease make it rather unlikely that this issue was 
a major confounder. In addition, control samples had also been stored at -80°C prior 
to use. Forth, we cannot comment on the possible role of complement activation 
products in terminal kidney failure requiring dialysis, as those patients were excluded 
from our study. Fifth, Patients stratification in tertiles is arbitrary and based on the 
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hypothesis that patients with complement activation products in the higher or lower 
tertile have a higher or lower complement activation. Sixth, the control group used for 
comparison of CAP levels was a cohort of healthy patients unadjusted to the baseline 
characteristics of the AHF cohort. Although our observation of increased complement 
activation is well in line with findings of previous studies 11, 13, 24 further studies will be 
required to determine the diagnostic as well pathogenic specificity of the observed 
complement activation in this acute heart failure cohort, in particular in relation to age, 
gender and comorbidity of the patients. In order to address this issue in our cohort, we 
performed an age-adjusted subgroup analysis in individuals with age of 60 to 69 and 
70 to 79 years respectively. In both subgroups we could confirm increased levels of 
C4d and sC5b-9. Interestingly, these two parameters further increased during the first 
days of in-hospital care, and were also higher in AHF patients without infectious trigger. 
This observation might point to a prominent role of the classical and/or lectin pathway 
of complement in AHF and pathogenic mechanisms that either have a delayed 
response to treatment or require more profound changes than those being achieved 
during the first days of acute medical care. Last, although our data point to pathogenic 
role of complement activation AHF, our data do not allow dissecting more detailed 
mechanisms, in particular with regard to the question whether complement activation 
occurred locally or systemically. Our primary hypothesis was, that heart failure induces 
complement activation that can be quantified in peripheral blood, but it is also possible 
that complement activation occurred more systemically being associated with or even 
leading to acute heart failure. The dissection of these mechanisms will require a more 
experimental approach.  
In conclusion, complement activation products, in particular C4d and sC5b-9 
suggesting activation via the classical and/or lectin pathway, seems to be associated 
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with AHF, as their levels are substantially increased at AHF presentation to the ED and 
changes during the AHF treatment. However, CAP did not have a prognostic value in 
AHF 
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Tables and figures 
Table 1. Baseline characteristics of the 179 patients with AHF 
  Age, ys. – median (IQR) 79 (70-84) 
  BMI, kg/cm2 - median (IQR) 26(23-30) 
  Sex, female (%)  80 (45) 
  NYHA class III-IV at admission (%) 168 (95) 
  Cardiovascular risk factors – no (%)  
Hypertension 136 (76) 
Diabetes 57 (32) 
Dyslipidemia 70 (41) 
Smoking 110 (61) 
  Medical history – (%)  
Coronary artery disease 102 (57) 
COPD 39 (22) 
Renal failure 76 (43) 
Malignant disease 34 (19) 
Atrial fibrillation 64 (36) 
  Clinical findings  
Systolic blood pressure – mmHg – median (IQR) 137 (122-160) 
Diastolic blood pressure – mmHg – median (IQR) 84 (72-96) 
Heart rate – median (IQR) 89 (75-111) 
Oxygen saturation – % (IQR)  96 (94-98) 
  ECG findings – (%)  
Sinus rhythm  88 (49) 
Bundle branch block 129 (72) 
  Radiographic findings – no (%)  
Cardiomegalie 105 (59) 
Apical redistribution 79 (44) 
Interstitial edema 49 (27) 
Alveolar edema 9 (5) 
  Laboratory findings – median (IQR)  
BNP (ng/l) 891 ( 476-1786) 
Creatinin (mg/dl) 104 (76-145) 
eGFR (mL/min/1.73 m2) 47 (31-73) 
CRP (mg/dl) 12 (4-40) 
Haemoglobin (g/l) 129 (116-143) 
Medication – no (%)  
ACE or AT2 inhibitor 110 (62) 
Calcium antagonist 59 (34) 
Diuretic 131 (73) 
Betablocker 105 (59) 
Statin 60 (34) 
Antiaggregantsa 76 (43) 
Anticoagulantb 73 (41) 
BMI, Body mass index; NYHA, New York heart association functional classification; COPD , Chronic obstructive 
pulmonary disease; BNP, B-Type natriuretic peptide; eGFR, estimated glomerular filtration rate measured with the 
Crockoft-Gault Equation; C-reactive protein per; ACE, angiotensin-converting-enzyme inhibitor; AT2, Angiotensin II 
receptor; bAspirin or Clopidogrel; cPhenprocoumon 
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Table 2.  Levels of complement activation products (C4d, C3a, sC5b-9) in a control group of 
healthy individuals and patients with AHF. Subgroup analysis were performed for patients 
with age between 60 and 69 years (n=15 in the control group, n=31 in the AHF group) and 
70-79 years (n= 15 in the control group, n=53 in the AHF group). 
 
 Control group (n=75)  AHF (n=179) p-value 
C3a baseline (ng/ml) 312 (187-435) 440 (232-715) <0.001 
60-69 years 354 (218-406) 354 (212-705) 0.432 
70-79 years 312 (219-655) 535 (336-809) 0.061 
C4d baseline (µg/ml) 1.75 (0.58-2.77) 6.73 (3.51-10.76) <0.001 
60-69 years 0.74 (0.00-1.13) 6.20 (2.92-12.70) <0.001 
70-79 years 1.51 (0.57-4.60) 7.58 (4.55-11.33) <0.001 
sC5b-9 baseline (ng/ml) 184 (154-252) 389 (287-540) <0.001 
60-69 years 180 (167-265) 326 (287-463) <0.001 
70-79 years 234 (172-373) 409 (302-574) 0.002 
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Table 3. Levels of complement activation products (C4d, C3a, sC5b-9) in patients with 
infectious as trigger of acute heart failure 
 Infection (n=84) Other triggers (n=95) p-value 
C3a baseline (ng/ml) 562 (343-807) 347 (186-639) <0.001 
C3a day 6 (ng/ml) 569 (313-860) 364 (199-624) <0.001 
C4d baseline (µg/ml) 7.79 (4.12-12.34) 5.71 (3.30-9.64) <0.001 
C4d day 6 (µg/ml) 9.14 (5.29-13.12) 7.27 (4.44-12.51) <0.001 
sC5b-9 baseline (ng/ml) 428 (345-582) 342 (263-485) <0.001 
sC5b-9 day 6 (ng/ml) 481 (346-630) 390 (273-576) <0.001 
Other triggers include dietary indiscretion, medication malcompliance, uncontrolled hypertension, myocardial ischemia, arrhythmia, 
progressive valvular disease, anemia, thyroid disorders, pulmonary causes 
 
Online Table 1. Levels of complement activation products (C4d, C3a, sC5b-9) in patients 
with coronary artery disease 
 
Online Table 2. Levels of complement activation products (C4d, C3a, sC5b-9) in patients with 
acute ischemia as trigger of acute heart failure 
 Acute Ischemia (n=13) Other triggers (n=166) p-value 
C3a baseline (ng/ml) 475 (233-644) 434 (232-715) 0.945 
C3a day 6 (ng/ml) 582 (279-802) 448 (253-768) 0.794 
C4d baseline (µg/ml) 9.64 (5.05-16.36) 6.51 (3.48-10.24) 0.051 
C4d day 6 (µg/ml) 10.40 (6.07-18.48) 8.57 (4.80-12.54) 0.236 
sC5b-9 baseline (ng/ml) 375 (332-610) 390 (282-532) 0.371 
sC5b-9 day 6 (ng/ml) 503 (320-837) 442 (305-592) 0.456 
Other triggers include dietary indiscretion, medication malcompliance, uncontrolled hypertension, infection, arrhythmia, progressive 
valvular disease, anemia, thyroid disorders, pulmonary causes 
 
 
  
 CAD  (n=102) Other cardiopathy (n=77) p-value 
C3a baseline (ng/ml) 416 (242-734) 457 (222-705) 0.690 
C3a day 6 (ng/ml) 513 (279-749) 411 (225-779) 0.510 
C4d baseline (µg/ml) 6.63 (3.33-10.69) 6.94 (3.94-12.16) 0.903 
C4d day 6 (µg/ml) 8.65 (4.62-13.86) 8.57 (4.89-11.87) 0.354 
sC5b-9 baseline (ng/ml) 383 (302-532) 395 (281-541) 0.720 
sC5b-9 day 6 (ng/ml) 413 (294-590) 456 (311-635) 0.612 
CAD, coronary artery disease 
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Online Table 3. Univariate logistic regression for the evaluation of predictors of low (1st 
tertile) and high (3rd tertile) levels of complement activation products at admission, 
respectively. In the 1st tertile (n=30) patients are included who had only levels of complement 
activation products (C4d, C3a and sc59b) being in the lowest tertile. In the 3rd tertile (n=30) 
patients are included who had only levels of complement activation products being in the 
highest tertile. 
 1st tertile vs 2nd and 3rd tertiles 3rd tertile vs 1st and 2nd tertiles 
 OR (95%CI) p-value OR (95%CI) p-value 
Age, ys.  0.99 (0.96-1.03) 0.785 0.98  (0.95-0-1.02) 0.258 
BMI, kg/cm2  0.99 (0.93-1.07) 0.969 1.03 (0.97-1.10) 0.319 
Reduced LVEF 1.67 (0.69-4.03) 0.255 0.52 (0.20-1.34) 0.179 
Sex, female  0.56 (0.25-1.29 0.174 0.79 (0.36-1.77) 0.571 
NYHA class 0.76 (0.38-1.48) 0.415 0.98 (0.50-1.89) 0.940 
Cardiovascular risk factors     
Hypertension 1.05 (0.42-2.64) 0.923 0.84 (0.35-2.06) 0.710 
Diabetes 0.37 (0.14-1.03) 0.058 0.90 (0.39-2.12) 0.812 
Dyslipidemia 1.45  (0.65-3.23) 0.364 2.03 (0.91-4.54) 0.086 
Active Smoking 0.20 (0.12-1.55) 0.202 1.44 (0.56-3.71) 0.450 
Medical history     
Previous AHF 1.13 (0.51-2.47) 0.765 1.85 (0.82-4.15) 0.137 
Coronary artery disease 0.82 (0.37-1.80) 0.617 1.33 (0.60-2.92) 0.485 
COPD 0.92 (0.35-2.44) 0.862 2.05 (0.87-4.85) 0.102 
Renal failure 1.23 (0.56-2.70) 0.610 1.04 (0.47-2.30) 0.915 
Malignant disease 0.61 (0.20-1.88) 0.390 1.38 (0.54-3.53) 0.508 
Hypertensive heart 
disease 
0.50 (0.18-1.41) 
0.190 
1.05 (0.44-2.51) 0.913 
Atrial fibrillation 0.99 (0.44-2.25) 0.989 0.57 (0.24-1.37) 0.210 
Liver Disease 0.34 (0.43-2.73) 0.313 1.26 (0.33-4.76) 0.734 
Clinical findings     
  Systolic blood pressure     
– mmHg – median (IQR) 
0.99 (0.98-1.00) 0.138 1.00 (0.98-1.01) 0.911 
  Diastolic blood 
pressure – mmHg – 
median (IQR) 
0.99 (0.97-1.01) 0.492 0.99 (0.97-1.01) 0.485 
  Heart rate – median 
(IQR) 
1.00 (0.99-1.02) 0.629 0.99 (0.97-1.00) 0.131 
  Oxygen saturation – % 
(IQR)  
1.08 (0.96-1.22) 0.199 0.95 (0.87-1.04) 0.252 
  Hepatojugular reflux – 
no (%) 
0.51 (0.18-1.45) 0.209 0.88 (0.36-2.16) 0.784 
  Jugular distension – no 
(%) 
1.53 (0.65-3.61) 0.330 0.44 (0.18-1.04) 0.062 
  Leg edema – no (%) 0.76 (0.33-1.77) 0.535 0.64 (0.28-1.46) 0.289 
  Sinus rhythm 0.89 (0.40-1.95) 0.765 1.69 (0.76-3.76) 0.196 
  Bundle branch block 1.63 (0.71-3.74) 0.245 0.24 (0.07-0.84) 0.025 
Radiologic signs of 
leftventricular AHFa 
0.66 (0.30-1.44) 0.293 0.47 (0.21-1.05) 0.065 
Laboratory findings     
  BNP (ng/l) 1.02 (1.00-1.04) 0.108 0.90 (0.83-0.97) 0.006 
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  eGFR  (mL/min/1. 
73m2) 
1.01 (0.99-1.02) 0.479 1.00 (0.99-1.01) 0.510 
  CRP (mg/dl) 
0.98 (0.96-1.00) 
0.049 1.00 (0.99-1.01) 0.427 
  Bilirubin (µmol/L) 1.01 (0.98-1.04) 0.588 1.01 (0.98-1.03) 0.735 
  ALAT (U/l) 1.00 (1.00-1.01) 0.283 0.96 (0.93-0.99) 0.028 
  ASAT (U/l) 1.00 (1.00-1.01) 0.617 0.99 (0.97-1.01) 0.236 
  INR 1.05 (0.80-1.38) 0.731 1.11 (0.86-1.44) 0.427 
  Albumin (g/l) 1.05 (0.96-1.14) 0.284 0.96 (0.89-1.04) 0.307 
  Haemoglobin (g/l) 1.01 (0.99-1.03) 0.303 1.00 (0.98-1.02) 0.745 
  Leucocyte (x 109/l) 0.92 (0.81-1.04) 0.183 1.05 (0.94-1.18) 0.377 
  Thrombocytes (x 109/l) 1.00 (1.00-1.01) 0.358 1.00 (1.00-1.01) 0.379 
Medication     
  ACE or AT2 inhibitor 2.93 (1.13-7.59) 0.027 1.10 (0.49-2.48) 0.817 
  Calcium Antagonist 0.99 (0.42-2.36) 0.982 0.82 (0.35-1.93) 0.654 
  Diuretic 0.34 (0.15-0.76) 0.009 1.57 (0.60-4.11) 0.359 
  Betablocker 0.66 (0.30-1.44) 0.293 1.07 (0.48-2.38) 0.870 
  Antiaggregantsb 0.75 (0.33-1.68) 0.483 0.75 (0.33-1.68) 0.483 
  Anticoagulantc 1.13 (0.51-2.51) 0.755 1.85 (0.84-4.06) 0.129 
  Statin 1.17 (0.50-2.73) 0.726 0.96 (0.42-2.21) 0.923 
BMI, Body mass index; NYHA, New York heart association functional classification; COPD , Chronic obstructive pulmonary disease; BNP, 
B-Type natriuretic peptide; eGFR, estimated glomerular filtration rate measured with the Crockoft-Gault Equation; C-reactive protein 
per; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; ACE, angiotensin-converting-enzyme inhibitor; AT2, 
Angiotensin II receptor; INR, international normalized ratio; a Radiologic signs for apical redistribution or interstitial or alveolar oedema; 
bAspirin or Clopidogrel; cPhenprocoumon; OR for continue variable are per increase in 1 Unit, for BNP OR are per increase in 100ng/l 
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Table 4. Multivariate logistic regression for the evaluation of predictors of low (1st tertile) and 
high (3rd tertile) levels of complement activation products at admission, respectively. In the 1st 
tertile (n=30) patients are included who had only levels of complement activation products 
(C4d, C3a and sc59b) being in the lowest tertile. In the 3rd tertile (n=30) patients are included 
who had only levels of complement activation products being in the highest tertile.  
 
Table 1 1st tertile vs 2nd and 3rd tertiles 3rd tertile vs 1st and 2nd tertiles 
 OR (95%CI)  p-value OR (95%CI) p-value 
Age, ys. – median (IQR) 1.03 (0.97-1.09) 0.320 0.97 (0.92-0-1.02) 0.227 
BMI, kg/cm2 - median 
(IQR) 
1.00 (0.89-1.13) 0.972 1.04 (0.93-1.15) 0.506 
Sex, female (%)  0.32 (0.09-1.14) 0.079 1.05 (0.37-3.01) 0.929 
Association with infection 0.23 (0.06-0.93) 0.039 2.17 (0.71-6.60) 0.174 
Diabetes 0.89 (0.22-3.47) 0.857 0.50 (0.14-1.80) 0.290 
Dyslipidemia 2.60  (0.84-8.10) 0.099 1.28 (0.44-3.73) 0.651 
Jugular distension – no 
(%) 
1.19 (0.39-3.68) 0.869 0.90 (0.29-2.81) 0.859 
Bundle branch block 0.70 (0.20-2.88) 0.758 0.49 (0.12-2.06) 0.328 
Radiologic signs of 
congestion 
0.51 (0.16-1.68) 0.267 0.59 (0.19-1.82) 0.359 
BNP (100 ng/l) 1.03 (0.99-1.07) 0.105 0.92 (0.85-1.00) 0.050 
CRP (mg/dl) 0.98 (0.94-1.01) 0.163 1.00 (0.99-1.01) 0.720 
ALAT (U/l) 1.00 (1.00-1.01) 0.487 0.94 (0.90-0.99) 0.011 
ACE or AT2 inhibitor 3.11 (0.86-11.30) 0.084 2.26 (0.74-6.91 ) 0.154  
Diuretic 0.58 (0.17-1.98) 0.381 1.81 (0.52-6.35) 0.353 
BMI, Body mass index; BNP, B-type Natriuretic Peptide; CRP, C-reactive protein; ALAT, alanine aminotransferase; ASAT, aspartate 
aminotransferase; ACE, angiotensin-converting-enzyme inhibitor; AT2, Angiotensin II receptor;  
Multivariate analysis included only patients without missing data (n= 151), 1st tertile n=23, 3rd tertile n=27. OR for continue variable 
are per increase in 1 Unit, for BNP OR are per increase in 100ng/l 
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Table 5. Univariate and multivariate Cox-regression analysis for 730 days mortality 
Table 1 Univariate Analysis 
Table 1 
Multivariate Analysis 
Table 1 
 HR (95%CI)  p-value HR (95%CI) p-value 
Age, ys. 1.05 (1.02-1.08) 0.001 1.02 (0.99-1.06) 0.207 
Sex, female  0.94 (0.58-1.54) 0.942 0.87 (0.50-1.51) 0.618 
Ischemic heart disease 1.15 (0.70-1.89) 0.580   
Reduced LVEF 
1.00 (0.57-1.76) 0.988 
  
Hypertension 1.54  (0.81-2.95) 0.189   
Diabetes 0.84 (0.49-1.43) 0.523   
Malignant Disease 1.94 (1.12-3.32) 0.012 1.48 (0.81-2.70) 0.208 
Liver disease 1.95 (0.93-4.11) 0.079 2.50 (1.05-5.92) 0.038 
Sinus Rhythm 1.18 (0.73-1.91) 0.499   
Bundle branch block 0.78 (0.45-1.38) 0.394   
ACE or AT2 inhibitor 0.39 (0.22-0.67) 0.001 0.60 (0.31-1.17) 0.135 
Betablocker 0.55 (0.33-0.90) 0.018 0.69 (0.39-1.21) 0.195 
Aspirin 0.70 (0.41-1.21) 0.200   
Clopidogrel 1.57 (0.78-3.18) 0.205   
Anticoagulant 0.67 (0.41-1.10) 0.115   
Statin 0.72 (0.43-1.20) 0.202   
Digoxin 0.76 (0.31-1.90) 0.562   
Spironolactone 0.73 (0.35-1.52) 0.395   
BNP (100 ng/l) 1.03 (1.01-1.05) 0.001 1.02 (1.00-1.04) 0.124 
eGFR 0.98 (0.97-0.99) <0.001 0.99 (0.97-1.00) 0.026 
CRP (mg/dl) 1.01 (1.01-1.02) <0.001 1.01 (1.01-1.02) <0.001 
Albumin (g/l) 0.89 (0.85-0.94) <0.001 0.96 (0.90-1.03) 0.246 
Haemoglobin (g/l) 0.98 (0.97-0.99) 0.015 1.00 (0.98-1.01) 0.589 
C3a 1.00 (1.00-1.00) 0.197 1.00 (1.00-1.00) 0.699 
C4d 0.99 (0.95-1.03) 0.598 0.99 (0.95-1.03) 0.540 
sC5b-9 1.00 (1.00-1.00) 0.817 1.00 (1.00-1.00) 0.717 
Reduced LVEF, Leftventricular ejection fraction lower than 45%; BNP, B-type Natriuretic Peptide;  eGFR, estimated glomerular filtration 
rate measured with the Crockoft-Gault Equation; CRP, C-reactive protein;  
HR for C3a, C4d, sc5b-9 in the multivariate model were obtained adding separately each complement activated product to the 
multivariate model. 
HR for continue variable are per increase in 1 Unit, for BNP OR are per increase in 100ng 
Multivariate analysis included only patients without missing data (n=169) 
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Figure 1. Schematic description of the complement pathways. 
 
 
 
 
  
27 
 
Figure 2 (a),(b),(c).  Levels of complement activation products (CAP) in plasma (C3a (a), 
C4d (b), sC5b-9 (c)) at day 1 and day 6 
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Figure 3 (a),(b),(c). Spreading plots with best fitting line for different CAPs. C3a and C4d (a, 
C3a and sC5b-9 (b), C4d and sC5b-9 (c)  
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Figure 4.  Prognostic accuracy of CAP for 730 days mortality  
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Figure 5 (a), (b), (c) Kaplan Meier for 730 days mortality for admission levels of C3a (a), C4d 
(b) and sC5b-9 (c) 
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